Carcinoid tumour management in haemodialysis: A case report

Nephrology

Volumn 17, Issue 2, 2012, Pages 198-

  Burke, Michael T ^a   Gray, Nicholas A ^a  

^a NAMBOUR GENERAL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; SEROTONIN;

ADULT; CANCER RECURRENCE; CANCER SURGERY; CARCINOID; CASE REPORT; CHEMOEMBOLIZATION; DIARRHEA; FLUSHING; HOME DIALYSIS; HUMAN; KIDNEY FAILURE; LETTER; LIVER METASTASIS; MALE; METASTATIC ILEAL CARCINOID; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; REFLUX NEPHROPATHY; SEROTONIN BLOOD LEVEL;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOID TUMOR; CHEMOEMBOLIZATION, THERAPEUTIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; ILEAL NEOPLASMS; KIDNEY FAILURE, CHRONIC; LIVER NEOPLASMS; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; RENAL DIALYSIS; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84856196411     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2011.01519.x     Document Type: Letter

References (4)

1. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV,. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008; 9: 61-72.
2. Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P,. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Aliment. Pharmacol. Ther. 2009; 30: 733-40.
3. Hofland LJ, Lamberts SW,. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev. 2003; 24: 28-47. (Pubitemid 36223278)
4. Adabala M, Jhaveri KD, Gitman M,. Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient. Nephrol. Dial. Transplant. 2010; 25: 3439-42.